ERBB2 and ovarian cancer: Majority of targeted therapy in breast cancer and ovarian cancer focus on HER-2, through CRISPR/Cas9 loss of function screen, Xiao-Fan Wan manifests that TALDO1 is critical for the survival of breast cancer cell line with the treatment of HER2 inhibitor (172).